Ultragenyx's Corporate Sustainability Journey—Ultragenyx
Ultragenyx Signs a License Agreement with Mereo for Setrusumab in Osteogenesis Imperfecta
Marin County's Ultragenyx Pharmaceutical reports Q2 loss of nearly $160 million
Press releases—Ultragenyx Pharmaceutical Inc.
Investors & Media—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical, Inc. Aktie News
Ultragenyx Fights for Cures Amid Rising R&D Costs - NAM
Press Release
Ultragenyx Pharmaceutical, Inc. Aktie News
Events & presentations—Ultragenyx Pharmaceutical Inc.
Press releases—Ultragenyx Pharmaceutical Inc.
Ultragenyx Overview | SignalHire Company Profile
Press releases—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Buy" from Brokerages - MarketBeat
GeneTx and Ultragenyx Announce Investigational New Drug
Press releases—Ultragenyx Pharmaceutical Inc.
Ultragenyx Issues 2022 ESG Report, Continuing To Enhance Its Leadership on Corporate Responsibility
Press releases—Ultragenyx Pharmaceutical Inc.
Events & presentations—Ultragenyx Pharmaceutical Inc.
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy - CureDuchenne
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, Quote & News - Stock Analysis
Articles about Ultragenyx Pharmaceutical Inc.
